Abstract
Elevated levels of fetal fibronectin (fFN) in cervicovaginal secretions beyond 20–22 weeks of gestation are used as a predictor of preterm birth in patients with corroborative symptoms and signs.
Aim: To assess the impact of introducing the fFN assay on the diagnosis, length of hospital stay and cost of managing patients presenting with symptoms of premature labour in our hospital.
Methods: The first 30 fFN‐tested patients (fFN group) were prospectively recruited and followed up until delivery. Hospital stay and management costs (costs of individual tests and treatment administered) and neonatal outcomes were compared with 30 matching historical controls.
Results: Overall management costs of the fFN‐group were comparable with controls (NZ$918 versus NZ$943 per patient, p = 0.44). The fFN‐group had a trend towards reduced length of hospital stay (p = 0.082), less tocolysis (p = 0.002) and use of steroids (p<0.001). The cost of managing an fFN‐positive patient was more than an fFN‐negative patient, but not statistically significant (NZ$1117 versus NZ$846, respectively, p = 0.11).
Conclusion: Despite a trend towards reduced hospital stay and less use of obstetric intervention, total expenditure in patient management has not reduced with the availability of the fFN assay in our hospital. This may only reflect the slow introduction of a new policy that with time may be implemented to full effect.